Clinical trial
Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory…
NCT00093704 · Jonsson Comprehensive Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00093704 |
|---|---|
| Title | Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma |
| Official title | EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Lymphoproliferative Disorder |
| Intervention type | Drug |
| Interventions | bortezomib + ganciclovir |
| Enrollment | 1 |
| Start date | Mar 1, 2005 |
| Primary completion | Jul 1, 2010 |
| First posted | Oct 8, 2004 |
| Last update posted | Jul 31, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: